{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:53:23Z","timestamp":1790229203645,"version":"4.1.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Community-acquired pneumonia (CAP) is a common infectious disease characterized by inflammation of the lung parenchyma in individuals who have not recently been hospitalized. It remains a significant cause of morbidity and mortality worldwide. Aspirin is a widely used drug, often administered to CAP patients. However, the benefits of aspirin remain controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We sought to determine whether aspirin treatment has a protective effect on the outcomes of CAP patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We selected patients with CAP from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Propensity score matching (PSM) balanced baseline differences. A multivariate Cox regression model assessed the relationship between aspirin treatment and 28-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3,595 patients were included, with 2,261 receiving aspirin and 1,334 not. After PSM, 1,219 pairs were matched. The 28-day mortality rate for aspirin users was 20.46%, lower than non-users. Multivariate Cox regression indicated aspirin use was associated with decreased 28-day mortality (HR 0.75, 95% CI 0.63\u20130.88,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). No significant differences were found between 325\u00a0mg\/day and 81\u00a0mg\/day aspirin treatments in terms of 28-day mortality, hospital mortality, 90-day mortality, gastrointestinal hemorrhage, and thrombocytopenia. However, intensive care unit (ICU) stay was longer for the 325\u00a0mg\/day group compared to the 81\u00a0mg\/day group (4.22 vs. 3.57 days,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.031).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Aspirin is associated with reduced 28-day mortality in CAP patients. However, 325\u00a0mg\/day aspirin does not provide extra benefits over 81\u00a0mg\/day and may lead to longer ICU stays.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1402386","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:48:32Z","timestamp":1726188512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Aspirin reduces the mortality risk of patients with community-acquired pneumonia: a retrospective propensity-matched analysis of the MIMIC-IV database"],"prefix":"10.3389","volume":"15","author":[{"given":"Guangdong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaolin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/s1473-3099(16)30267-5","article-title":"Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study","volume":"16","author":"Aliberti","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"Bmj"},{"key":"B3","doi-asserted-by":"publisher","first-page":"ofy010","DOI":"10.1093\/ofid\/ofy010","article-title":"Incidence, etiology, and outcomes of community-acquired pneumonia: a population-based study","volume":"5","author":"Bjarnason","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1365-2362.1985.tb00294.x","article-title":"Effect of incremental doses of aspirin on bleeding time, platelet aggregation and thromboxane production in patients with cerebrovascular disease","volume":"15","author":"Boss","year":"1985","journal-title":"Eur. J. Clin. Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12872-016-0347-7","article-title":"Adverse clinical outcomes associated with a low dose and a high dose of aspirin following percutaneous coronary intervention: a systematic review and meta-analysis","volume":"16","author":"Bundhun","year":"2016","journal-title":"BMC Cardiovasc Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2014.07.985","article-title":"Platelet activation is associated with myocardial infarction in patients with pneumonia","volume":"64","author":"Cangemi","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.amjmed.2008.06.030","article-title":"Prior statin use is associated with improved outcomes in community-acquired pneumonia","volume":"121","author":"Chalmers","year":"2008","journal-title":"Am. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"625834","DOI":"10.3389\/fpubh.2021.625834","article-title":"Association between aspirin use and decreased risk of pneumonia in patients with cardio-cerebra-vascular ischemic disease: a population-based cohort study","volume":"9","author":"Chen","year":"2021","journal-title":"Front. Public Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1055\/s-0041-1726096","article-title":"Contemporary clinical use of aspirin: mechanisms of action, current concepts, unresolved questions, and future perspectives","volume":"47","author":"Christiansen","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"key":"B10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jinf.2011.06.009","article-title":"Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review","volume":"63","author":"Corrales-Medina","year":"2011","journal-title":"J. Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/circulationaha.111.040766","article-title":"Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality","volume":"125","author":"Corrales-Medina","year":"2012","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0232176","DOI":"10.1371\/journal.pone.0232176","article-title":"Analysis of adult disease characteristics and mortality on MIMIC-III","volume":"15","author":"Dai","year":"2020","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.14520","article-title":"The aspirin story - from willow to wonder drug","volume":"177","author":"Desborough","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17476348.2019.1675517","article-title":"Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients","volume":"14","author":"El-Gazzar","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/thx.2008.109785","article-title":"New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality","volume":"64","author":"Ewig","year":"2009","journal-title":"Thorax"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e001595","DOI":"10.1161\/jaha.114.001595","article-title":"Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin","volume":"4","author":"Falcone","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01556-18","article-title":"A hypothesis-generating study of the combination of aspirin plus macrolides in patients with severe community-acquired pneumonia","volume":"63","author":"Falcone","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/mcc.0000000000000340","article-title":"Community-acquired pneumonia: still a major burden of disease","volume":"22","author":"Feldman","year":"2016","journal-title":"Curr. Opin. Crit. Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1378\/chest.111.4.1094","article-title":"Effect of acetylsalicylic acid on pulmonary gas exchange in patients with severe pneumonia: a pilot study","volume":"111","author":"Ferrer","year":"1997","journal-title":"Chest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pharmthera.2013.08.005","article-title":"Mechanisms of aspirin resistance","volume":"141","author":"Floyd","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12265-013-9529-1","article-title":"Antiplatelet therapy: targeting the TxA2 pathway","volume":"7","author":"Fontana","year":"2014","journal-title":"J. Cardiovasc Transl. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/s0140-6736(18)31924-x","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2002795","DOI":"10.1183\/13993003.02795-2020","article-title":"Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database","volume":"57","author":"Hamilton","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/s0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"172762","DOI":"10.1016\/j.ejphar.2019.172762","article-title":"Aspirin and its pleiotropic application","volume":"866","author":"Hybiak","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41597-022-01899-x","article-title":"MIMIC-IV, a freely accessible electronic health record dataset","volume":"10","author":"Johnson","year":"2023","journal-title":"Sci. Data"},{"key":"B27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cyto.2018.07.019","article-title":"Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients","volume":"113","author":"Karhu","year":"2019","journal-title":"Cytokine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/jir.S86917","article-title":"Hypoglycemic agents and potential anti-inflammatory activity","volume":"9","author":"Kothari","year":"2016","journal-title":"J. Inflamm. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2334-14-47","article-title":"Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniae invasive syndrome","volume":"14","author":"Lee","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"106098","DOI":"10.1016\/j.rmed.2020.106098","article-title":"Platelets in chronic obstructive pulmonary disease: an update on pathophysiology and implications for antiplatelet therapy","volume":"171","author":"Mallah","year":"2020","journal-title":"Respir. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/ehf2.13688","article-title":"Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis","volume":"9","author":"Mujaj","year":"2022","journal-title":"Esc. Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"220123","DOI":"10.1183\/16000617.0123-2022","article-title":"Severe community-acquired pneumonia","volume":"31","author":"Niederman","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MCA.0b013e32835d7610","article-title":"Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial","volume":"24","author":"Oz","year":"2013","journal-title":"Coron. Artery Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.amjcard.2007.12.038","article-title":"Platelet inhibition by aspirin 81 and 325 mg\/day in men versus women without clinically apparent cardiovascular disease","volume":"101","author":"Qayyum","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/joim.13485","article-title":"Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia: a long-term nationwide study","volume":"292","author":"R\u00f6gnvaldsson","year":"2022","journal-title":"J. Intern Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0283163","DOI":"10.1371\/journal.pone.0283163","article-title":"Aspirin modulates production of pro-inflammatory and pro-resolving mediators in endothelial cells","volume":"18","author":"Rood","year":"2023","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/jci77812","article-title":"The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux","volume":"126","author":"Samuel","year":"2016","journal-title":"J. Clin. Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejphar.2013.09.032","article-title":"Drug\/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets","volume":"721","author":"Saxena","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"8663","DOI":"10.1038\/s41598-021-88007-y","article-title":"Impact of chronic respiratory diseases on re-intubation rate in critically ill patients: a cohort study","volume":"11","author":"Shen","year":"2021","journal-title":"Sci. Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann. Intern Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"462","DOI":"10.2165\/00003088-199019060-00004","article-title":"The effect of respiratory disorders on clinical pharmacokinetic variables","volume":"19","author":"Taburet","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.88","article-title":"Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial","volume":"313","author":"Torres","year":"2015","journal-title":"Jama"},{"key":"B43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat. New Biol."},{"key":"B44","first-page":"27","article-title":"Inhibitors of prostaglandin, prostacyclin, and thromboxane synthesis","volume":"4","author":"Vane","year":"1978","journal-title":"Adv. Prostaglandin Thromboxane Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/cid\/cix164","article-title":"Cardiovascular complications and short-term mortality risk in community-acquired pneumonia","volume":"64","author":"Violi","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1042\/cs20171006","article-title":"Aspirin-triggered resolvin D1 reduces pneumococcal lung infection and inflammation in a viral and bacterial coinfection pneumonia model","volume":"131","author":"Wang","year":"2017","journal-title":"Clin. Sci. (Lond)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e033882","DOI":"10.1161\/jaha.123.033882","article-title":"Chronic obstructive pulmonary disease exacerbations increase the risk of subsequent cardiovascular events: a longitudinal analysis of the COPDGene study","volume":"13","author":"Yang","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/07853890.2018.1518580","article-title":"A new prediction model for assessing the clinical outcomes of ICU patients with community-acquired pneumonia: a decision tree analysis","volume":"51","author":"Zhang","year":"2019","journal-title":"Ann. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"Jama"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1402386\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:48:36Z","timestamp":1726188516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1402386\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":49,"alternative-id":["10.3389\/fphar.2024.1402386"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1402386","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"article-number":"1402386"}}